FindTrial
Sign In

Retrospective real-world study on evaluating the efficacy of disitamab vedotin in treating HER2-positive metastatic urothelial carcinoma using HER2 PET-CT

Retrospective real-world study on evaluating the efficacy of disitamab vedotin in treating HER2-positive metastatic urothelial carcinoma using HER2 PET-CT

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600120370
Enrollment
Unknown
Registered
2026-03-13
Start date
2026-03-15
Completion date
Unknown
Last updated
2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urothelial carcinoma

Interventions

disitamab vedotin treatment group:None

Sponsors

Huashan hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients who visited the Department of Urology, Huashan Hospital, Shanghai, between January 1, 2023, and August 1, 2025; 2. Patients who underwent HER2 PET-CT imaging; 3. Patients who initiated at least four cycles of disitamab vedotin (administered once every three weeks) within three months after the PET-CT examination.

Exclusion criteria

Exclusion criteria: 1. Incomplete medical records; 2. Receipt of chemotherapy or other non-disitamab vedotin antitumor therapies during the study period; 3. Failure to undergo disease assessment (e.g., CT or MRI) within 3–6 months after initiation of disitamab vedotin.

Design outcomes

Primary

MeasureTime frame
Objective response rate;—

Secondary

MeasureTime frame
overall survival;Recurrence free survival;—

Countries

China

Contacts

Public ContactJiang Haowen

Huashan hospital, Fudan University

575811088@qq.com+86 181 0188 1202

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 20, 2026